Type of serum influences the rituximab dependent cytotoxicity and apoptosis of chronic lymphocytic leukemia cells in vitro

被引:0
作者
Ziolkowska, Ewelina [1 ]
Franiak-Pietryga, Ida [2 ]
Cebula-Obrzut, Barbara [3 ]
Blonski, Jerzy Z. [1 ]
Robak, Tadeusz [1 ]
Smolewski, Piotr [3 ]
Korycka-Wolowiec, Anna [1 ]
机构
[1] Med Univ Lodz, Dept Hematol, PL-93510 Lodz, Poland
[2] Copernicus Mem Hosp, Lab Clin & Transplant Immunol & Genet, PL-93513 Lodz, Poland
[3] Med Univ Lodz, Dept Expt Hematol, PL-93510 Lodz, Poland
来源
POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ | 2012年 / 66卷
关键词
chronic lymphocytic leukemia; Rituximab; Fetal Calf Serum; Autologous Serum; AB-Serum; apoptosis; PURINE NUCLEOSIDE ANALOGS; CLL CELLS; FLUDARABINE; CYCLOPHOSPHAMIDE; ALEMTUZUMAB; COMPLEMENT; INDUCTION; MECHANISM; CHEMOIMMUNOTHERAPY; ACTIVATION;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Purpose: The aim of the study was to compare the influence of types of serum on the in vitro viability and on either spontaneous or rituximab (RIT)-induced apoptosis of chronic lymphocytic leukemia (CLL) cells. Methods: The influence of fetal calf serum (FCS), patients' autologous serum (AS) and human AB-serum (ABS), used alone and in combinations consisting of two of them (v/v-1:1), on RIT-dependent cytotoxicity, apoptosis, detection of active forms of caspases-3,-9,-8 and disruption of mitochondrial membrane potential (Delta Psi(m)) were assessed by flow cytometry. RIT was used at the concentration of 10 mu g/ml. The spontaneous apoptosis was assessed in culture without RIT. Results: AS revealed the protective action on CLL cells, however this serum added in vitro to the culture either alone or in combination with FCS was the only one to allow RIT to exert its cytotoxic action against CLL cells. RIT-induced apoptosis involved changes in Delta Psi(m) and activation of caspases-3,-8,-9 when AS+FCS was applicated. Drug induced apoptosis (DIA) was 6.02 and 0.34, when FCS+AS and FCS alone were used, respectively (p<0.01). The RIT-dependent cytotoxic effect decreased when FCS+AS or FCS+ABS were used, as compared to effect of AS used separately. The cytotoxic effect of RIT did not depend on drug concentration, but on the type of serum added to the culture. Conclusions: The strongest cytotoxic effect of RIT in the presence of AS suggests that this drug activity towards CLL cells is enhanced by known cytotoxic mechanisms, caspase-dependent apoptotic pathway and possible influence of other extracellular factors present in the patients' sera.
引用
收藏
页码:730 / 738
页数:9
相关论文
共 20 条
[1]   Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM [J].
Alonso, Roberto ;
Lopez-Guerra, Monica ;
Upshaw, Ramanda ;
Bantia, Shanta ;
Smal, Caroline ;
Bontemps, Francoise ;
Manz, Chantal ;
Mehrling, Thomas ;
Villamor, Neus ;
Campo, Elias ;
Montserrat, Emili ;
Colomer, Dolors .
BLOOD, 2009, 114 (08) :1563-1575
[2]   Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species [J].
Bellosillo, B ;
Villamor, N ;
López-Guillermo, A ;
Marcé, S ;
Esteve, J ;
Campo, E ;
Colomer, D ;
Montserrat, E .
BLOOD, 2001, 98 (09) :2771-2777
[3]   The antiapoptotic effects of blood constituents in patients with chronic lymphocytic leukemia [J].
Bomstein, Y ;
Yuklea, M ;
Radnay, J ;
Shapiro, H ;
Afanasyev, F ;
Yarkoni, S ;
Lishner, M .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (05) :290-295
[4]   The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction [J].
Byrd, JC ;
Kitada, S ;
Flinn, IW ;
Aron, JL ;
Pearson, M ;
Lucas, N ;
Reed, JC .
BLOOD, 2002, 99 (03) :1038-1043
[5]  
Chow KU, 2002, HAEMATOLOGICA, V87, P33
[6]  
Darzynkiewicz Zbigniew, 2002, Methods Mol Biol, V203, P69
[7]   Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro [J].
Furlan, Anna ;
Villanova, Federica ;
Pietrogrande, Francesco ;
Celadin, Marilena ;
Sanzari, Mariella ;
Vianello, Fabrizio .
LEUKEMIA & LYMPHOMA, 2010, 51 (01) :107-113
[8]   Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines [J].
Hallek, Michael ;
Cheson, Bruce D. ;
Catovsky, Daniel ;
Caligaris-Cappio, Federico ;
Dighiero, Guillaume ;
Doehner, Hartmut ;
Hillmen, Peter ;
Keating, Michael J. ;
Montserrat, Emili ;
Rai, Kanti R. ;
Kipps, Thomas J. .
BLOOD, 2008, 111 (12) :5446-5456
[9]   Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia [J].
Johnson, Amy J. ;
Wagner, Amy J. ;
Cheney, Carolyn M. ;
Smith, Lisa L. ;
Lucas, David M. ;
Guster, Sara K. ;
Grever, Michael R. ;
Lin, Thomas S. ;
Byrd, John C. .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (05) :837-844
[10]   Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia [J].
Keating, MJ ;
O'Brien, S ;
Albitar, M ;
Lerner, S ;
Plunkett, W ;
Giles, F ;
Andreeff, M ;
Cortes, J ;
Faderl, S ;
Thomas, D ;
Koller, C ;
Wierda, W ;
Detry, MA ;
Lynn, A ;
Kantarjian, H .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4079-4088